Dendritic cells control tertiary lymphoid structure development and maintenance in cancer
Authors:
Top Cited Papers
- 16 July 2026
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 393 (6808) , eady1678
Abstract
Tertiary lymphoid structures (TLSs) are associated with immunotherapy response, yet the mechanisms controlling their formation and maintenance remain unclear. Using spatial transcriptomics and multiplex imaging across human tumors, we found that CCR7 + mature dendritic cells (DCs) accumulate in TLSs. In a mouse non–small cell lung cancer model that forms mature TLSs, we show that early TLS development requires interferon-γ (IFN-γ)–driven type 1 conventional dendritic cell (cDC1) maturation, migration to tumor-draining lymph nodes (tdLNs), and T cell recruitment. As tumors progress, TLSs persist independently of tdLN T cell egress, coinciding with cDC1 accumulation within intratumoral CCL19 stromal hubs. There, cDC1–major histocompatibility complex class 1 (MHC-I) and –MHC-II concomitant antigen presentation, along with CD40 signaling, sustain TLS, T follicular helper (T FH ) cell pool, germinal centers, and tumor-specific immunoglobulin G (IgG). These findings highlight local mature cDC1s as key TLS orchestrators and potential targets to enhance antitumor TLS function.Keywords
Funding Information
- National Institutes of Health (K00 CA223043)
- National Institutes of Health (U24 CA224319, R01 DK1222853, U2C ES030859, DA055434, 1R01 HL166720-01A1, U01OH012621)
- National Institutes of Health (CA224319, DK124165, CA263705 and CA196521)
- National Institutes of Health (R01 AI153363)
- National Institutes of Health (CA257195, CA254104 and CA154947)
- National Institutes of Health (R37CA230636, R01CA251155)
- National Institutes of Health (T32GM146636)
- National Institutes of Health (R21AI180874, R21AI176069, R01AI160706 and R01DK130425)
- National Cancer Institute (F30CA301790)
- Cancer Research Institute (CRI12960)
- National Cancer Institute (K99CA293148)
- Tisch Cancer Institute (P30 CA196521)
- American Federation for Aging Research
- Tisch Cancer Institute (P30 CA196521)
- Damon Runyon Cancer Research Foundation (Rachleff Innovator Award.)
- American Association for Cancer Research (21-40-12-MATT)
- Portuguese Foundation for Science and Technology (2023.15874.PEX)
- Portuguese Foundation for Science and Technology (2024.17879.PEX)
- European Research Council (CoG grant artFibro 101088596)
- Boehringer Ingelheim
- Bodossaki Foundation (9755)
- Caribou Biosciences, Inc.
This publication has 93 references indexed in Scilit:
- CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasisCancer Cell, 2024
- Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumorsCancer Cell, 2024
- A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunityCancer Cell, 2023
- Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancerCancer Cell, 2022
- Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratificationCancer Cell, 2021
- Gene Set Knowledge Discovery with EnrichrCurrent Protocols, 2021
- Type 1 conventional dendritic cells and interferons are required for spontaneous CD4+ and CD8+ T‐cell protective responses to breast cancerClinical & Translational Immunology, 2021
- Cell Detection with Star-Convex Polygons2018
- Batf3‐dependent CD103+ dendritic cells are major producers of IL‐12 that drive local Th1 immunity against Leishmania major infection in miceEuropean Journal of Immunology, 2014
- p53 mutations are absent from carcinogen‐induced mouse liver tumors but occur in cell lines established from these tumorsMolecular Carcinogenesis, 1992